FDA Lashes Out at Latisse

brooke+shields+latisse FDA Lashes Out at Latisse

The Food and Drug Administration recently issued a warning to Allergan Inc., stating that the website for Latisse (a prescription eyelash lengthener) is misleading because it omits and minimizes risks associated with the product.

In a letter dated September 10, the FDA warns that latisse.com misbrands Latisse – in violation of the Federal Food, Drug, and Cosmetic Act – because it does not clearly convey the consequences that may result from use of the drug, which include:

Iris pigmentation
Lid pigmentation
Hair growth outside the treatment area
Intraocular inflammation
Potential for contamination and infections
Absorption by soft contact lenses

To read the letter in its entirety, .

Leave a Reply

Your email address will not be published. Required fields are marked *